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Combined suicide and cytokine gene therapy for
peritoneal carcinomatosis
C Lechanteur, P Delvenne, F Princen, M Lopez, G Fillet, J Gielen, M-P Merville, V Bours
Abstract
Background—Gene therapy is a novel
approach for the treatment of cancers,
and tumours disseminated in the perito-
neal cavity are suitable for in situ delivery
of a therapeutic gene.
Aims—The eYcacy of a therapy combin-
ing a suicide gene (herpes simplex virus
type I thymidine kinase (HSV-TK)) and
cytokine genes was investigated in a model
of peritoneal carcinomatosis induced by
colon carcinoma cells in syngeneic rats.
Material and methods—Pre-established
macroscopic tumours in BDIX rats were
treated by intraperitoneal injections of
retrovirus producing cells (FLYA13 TK,
FLYA13 granulocyte macrophage-colony
stimulating factor (GM-CSF), FLYA13
interleukin 12 (IL-12)) and ganciclovir
(GCV).
Results—TK/GCV treated animals showed
a slight increase in survival time (72 days)
compared with the control group (63 days)
while the association of cytokine and
TK/GCV gene therapy resulted in signifi-
cantly improved survival, with a large
proportion of animals remaining tumour
free on day 480 (60% and 40% for TK/GCV/
GM-CSF and TK/GCV/IL-12 treated ani-
mals, respectively). Histological analysis
of treated animals showed that the re-
maining tumour nodes were infiltrated by
mononuclear cells but no major diVer-
ences were observed between the various
treatments. Immunohistochemical analy-
sis revealed that lymphoid CD4+ and CD8+
T cells as well as macrophages accumu-
lated outside untreated tumour nodes
while CD8+ and CD25+ activated T cells
and macrophages heavily infiltrated the
tumours after the diVerent treatments.
Conclusions—Our data indicate that com-
bined suicide and cytokine gene therapy is
a powerful approach for the treatment of
macroscopic peritoneal carcinomatosis.
(Gut 2000;47:343–348)
Keywords: gene therapy; thymidine kinase; interleukin
12; granulocyte macrophage-colony stimulating factor;
peritoneal carcinomatosis
Suicide gene therapy is based on the intracellu-
lar delivery of a gene coding for an enzyme that
transforms a prodrug into a cytotoxic
product.1 2 A widely used suicide gene codes
for the herpes simplex virus type I thymidine
kinase (HSV-TK) which phosphorylates nucle-
oside analogues such as ganciclovir (GCV) to
monophosphate metabolites. Further phos-
phorylation by endogenous kinases leads to
formation of cytotoxic ganciclovir triphos-
phate.
We previously demonstrated the eYcacy of
HSV-TK mediated gene therapy for peritoneal
carcinomatosis induced by colorectal adeno-
carcinoma cells in a syngeneic immuno-
competent animal model.3 4 Other investigators
have explored the in vivo antitumour activity of
the TK gene5–10 as well as its therapeutic eVect
in clinical trials.11 However, its eYcacy is
limited by its low in vivo transduction eY-
ciency. Two approaches can be considered to
improve the therapeutic eYcacy of a suicide
gene. Firstly, new vectors are being developed
to increase the eYciency of gene delivery. Sec-
ondly, as only a small number of cells are
transduced, the bystander eVect, a mechanism
allowing the killing of untransduced adjacent
cells, is crucial and novel strategies are
designed to render it more eYcient.
Interestingly, a strong bystander eVect was
observed in our animal model3 and in other
experimental systems.6 12 13 Several mecha-
nisms have been proposed to explain this
eVect, such as the transfer of apoptotic vesicles
between adjacent cells or metabolic coopera-
tion through gap junctions. However, several
studies have indicated that in vivo, immunity
plays an important role in the bystander eVect
after TK/GCV gene therapy.14
The aim of our study was to boost the
bystander eVect to achieve longlasting survival
and tumour eradication in our model by com-
bined cytokine and TK/GCV gene therapy.
Interleukin 12 (IL-12)15–21 and granulocyte
macrophage-colony stimulating factor
(GM-CSF)22–25 are two cytokines that have
been used successfully in immunotherapy in
diVerent models of established tumours. We
chose to use retroviral vectors as such vectors
were previously demonstrated to be eYcient in
our model. Moreover, adenoviral vectors can
lead to important inflammatory reactions that
could be deleterious in a strategy with repeated
injections of vectors delivering cytokine genes.
Our results demonstrated that the association
of IL-12 or GM-CSF in situ expression with
retroviral HSV-TK gene therapy and GCV
treatment significantly improved survival rates
and the proportion of tumour free survivors.
Abbreviations used in this paper: TK, thymidine
kinase; HSV, herpes simplex virus; IL-12, interleukin
12; GM-CSF, granulocyte macrophage-colony
stimulating factor; GCV, ganciclovir; HBSS, Hanks’
balanced salt solution; PCR, polymerase chain
reaction; PBS, phosphate buVered saline; BSA, bovine





















V Bours, Medical Oncology,
CHU B35, University of
Liège, Sart-Tilman





 on 4 February 2009 gut.bmj.comDownloaded from 
Methods
ANIMALS, VECTORS, AND CELL LINES
Eight week old syngeneic BDIX rats were pur-
chased from IVa-Credo (l’Arbresle, France).
DHD/K12 Prob cells, FLYA13 packaging
cells, and HSV-TK and BAG retroviral vectors
have been described previously.3 4
In the GM-CSF and IL-12 retroviral vectors
(MoMuLV), murine GM-CSF or IL-12 p40
and p35 genes were placed under the control of
the first long terminal repeat and the neomycin
resistance gene was driven by an SV-40
promoter. To achieve balanced expression of
both the p40 and p35 subunits of mIL-12, we
used a bicistronic vector that contains an inter-
nal ribosome entry site derived from the
encephalomyocarditis virus.
GM-CSF and IL-12 coding sequences were
amplified by polymerase chain reaction (PCR)
from the pcDNA1 GM-CSF or IL-12 plasmids
using Bam HI primers, and PCR products
(500 bp) were inserted at the Bam HI site of
the BAG retroviral vector instead of the lac Z
gene. The pcDNA1 GM-CSF and pcDNA1
IL-12 expression vectors were generous
gifts from Professor K Thielemans (Laboratory
of Haematology and Immunology, VUB,
Brussels, Belgium).
The integrity of the GM-CSF and IL-12 p40
and p35 DNA sequences was confirmed by
DNA sequencing.
IL-12 and GM-CSF retroviral vectors were
transfected in the FLYA13 packaging cell line
by lipofection (DOTAP, Boehringer Mann-
heim, Germany). Colonies were isolated by
G418 selection (geneticin: active concentration
0.5 mg/ml) and expanded.
CYTOKINE ASSAYS
Secretion of IL-12 and GM-CSF by liposome
transfected packaging cells was determined
using the Quantiquine ELISA kit (R&D
Systems, Wiesbaden, Germany) for detection
of murine GM-CSF and the Intertest-12x
ELISA kit (Genzyme, Cambridge, Massachu-
setts, USA) for quantification of mouse IL-12
p70. Briefly, 106 transduced cells were plated in
25 cm2 T flasks with 5 ml of culture medium
supplemented with G418 (0.5 mg/ml). Forty
eight hours later supernatants were centrifuged
and tested for mIL-12 or mGM-CSF produc-
tion by ELISA. Results were expressed in
ng/106 cells/48 hours.
IN VIVO TRANSDUCTION
BDIX rats were injected intraperitoneally on
day 0 with 106 DHD/K12 live parental tumour
cells. On days 7, 14, and 21, the animals
received three intraperitoneal injections of
30×106 retrovirus producing FLYA13-TK cells
per animal with or without 20×106 cells
producing GM-CSF or IL-12 retroviruses
(FLYA13 GM-CSF or FLYA13 IL-12). They
were treated with either GCV (150 mg/kg/day)
diluted in Hanks’ balanced salt solution
(HBSS, Life Technologies, Gaithersburg,
Maryland, USA) from days 10–13, 17–20, and




Samples of tumours on visceral peritoneum
were excised, snap frozen on dry ice using
Tissue-Tek and stored at −70°C. Sections
(5 µm) were obtained with a cryostat, fixed
with carbowax, and stained with haematoxylin-
eosin for histological analysis or fixed with cold
acetone for 10 minutes and immunostained
with specific antibodies for detection of infil-
trating cells using the peroxidase method. For
this purpose, sections were incubated for 15
minutes in phosphate buVered saline
(PBS)/1% bovine serum albumin (BSA) and
then overnight at 4°C with monoclonal anti-
bodies diluted in PBS/1% BSA. We used the
following antibodies: antimacrophages (ED1,
1/500), anti-CD8 (MRC OX8, 1/100), anti-
CD4 (MRC OX35, 1/500), anti-CD25 (MRC
OX39, 1/100), and anti-NK/LAK cells (3.2.3.,
1/50). These are specific mouse monoclonal
GCV GCV GCV
DHD/K12 cells Retrovirus producing cells
0 10 20 30
Time (days)
Figure 1 Tumour response after gene therapy with
thymidine kinase/ganciclovir (TK/GCV) plus cytokines.
Rats injected with DHD/K12 cells received three
intraperitoneal injections of herpes simplex virus type I
thymidine kinase (HSV-TK) retrovirus producing
FLYA13 TK cells together with cytokine retrovirus
producing FLYA13 granulocyte macrophage-colony
stimulating factor (GM-CSF) or FLYA13 interleukin 12
(IL-12) cells. Each injection was followed by treatment with
GCV or Hanks’ balanced salt solution (HBSS). (Top)
Protocol for intraperitoneal delivery of retrovirus producing
cells and GCV treatment. Each group (six animals/group)
was injected intraperitoneally with 106 DHD/K12 cells on
day 0. The HSV-TK,GM-CSF, and IL-12 producing cells
FLYA13 TK, FLYA13 GM-CSF, and FLYA13 IL-12
were injected intraperitoneally on days 7, 14, and 21. For
the GCV treated groups, the first treatment was
administered from days 10–13, the second from days
17–20, and the third from days 24–27. Treatment
comprised 150 mg/kg of GCV once a day. At the same
time, the control group received 10 ml of HBSS once daily.
(Bottom) Animals were killed on day 30 and a
representative picture of the peritoneal cavity is shown: (A)
control rat, (B) rat treated with TK/GCV, (C) rat treated
with TK/GCV/IL-12, and (D) rat treated with
TK/GCV/GM-CSF.
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antirat antibodies and were purchased from
Serotec (Oxford, UK). After washing in PBS,
slides were stained with a peroxidase conju-
gated goat antimouse IgG antibody (Serotec)
1/50 in PBS/1% BSA for 30 minutes at room
temperature, washed, and positive cells visual-
ised using diaminobenzidine as the chro-
mogen.
STATISTICS
Kaplan-Meyer curves were established for each
group and survival rates were compared using
the log rank test.
Results
RETROVIRUS PRODUCING CELL LINES AND
CYTOKINE EXPRESSION
In this study we used the FLYA13 packaging
cell line which is known to produce high titres
of retroviruses resistant to inactivation by
human serum.26 In previous studies we gener-
ated an HSV-TK retrovirus producing cell line
(FLYA13 TK).4 Two other cell lines were gen-
erated (FLYA13 IL-12 and FLYA13 GM-
CSF) by transfection of a retroviral vector
(MoMuLV-derived) containing IL-12 p40 and
p35 or GM-CSF cDNAs, respectively. After
G418 selection, we measured the number of
retroviral particles produced by the diVerent
cell lines and reproducibly found a titre of
2×105 plaque forming units (pfu)/ml for
FLYA13 TK cells, 104 pfu/ml for FLYA13
IL-12 cells, and 105 pfu/ml for FLYA13
GM-CSF cells.
The FLYA13 IL-12 and FLYA13 GM-CSF
retrovirus producing cell lines were also
analysed for cytokine expression. FLYA13
IL-12 cells produced 60 ng of IL-12/106
cells/48 hours and FLYA13 GM-CSF cells
30 ng of GM-CSF/106 cells/48 hours (data not
shown).
TREATMENT OF RATS BEARING ESTABLISHED
TUMOURS
We investigated the eYciency of HSV-TK gene
therapy combined with cytokine gene therapy
in a model of peritoneal carcinomatosis
induced by DHD/K12 colorectal adenocarci-
noma cells in syngeneic BDIX rats. BDIX rats
were injected intraperitoneally on day 0 with
106 DHD/K12 cells and received three intra-
peritoneal injections of retrovirus producing
FLYA13 TK cells on days 7, 14, and 21 with or
without FLYA13 IL-12 or FLYA13 GM-CSF
cells. Rats were treated with GCV (150 mg/kg/
day) from days 10–13, 17–20, and 24–27.
Control animals were injected with FLYA13
TK cells and treated with HBSS buVer alone
according to the same schedule as the GCV
treated group (fig 1A).
At the end of the protocol (day 30), one ani-
mal from each group was killed and peritoneal
Figure 2 Survival of rats treated with thymidine
kinase/ganciclovir (TK/GCV) and cytokine genes. Five
animals from each group were monitored until they died. In
the group who received herpes simplex virus type I
thymidine kinase (HSV-TK) and granulocyte
macrophage-colony stimulating factor (GM-CSF)
producing FLYA13 cells, three of five animals were still
alive and tumour free on day 480 while two of five animals
were still alive at the same time in the HSV-TK/interleukin
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Figure 3 Standard histology of the tumours.
Haematoxylin-eosin staining of intraperitoneal tumours
from (A) control (100× magnification) or (B, C) treated
animals (100× and 200× magnification, respectively).
Combined gene therapy for peritoneal carcinomatosis 345
www.gutjnl.com
 on 4 February 2009 gut.bmj.comDownloaded from 
dissemination of the tumour was assessed by
direct abdominal examination (fig 1B). The
peritoneal cavity of the control animal was
completely invaded by tumour nodes (fig 1A)
while the TK/GCV treated animal showed a
highly reduced tumour burden (fig 1B). Com-
bined therapies (TK/GCV/IL-12 (fig 1C) or
TK/GCV/GM-CSF (fig 1D)) resulted in
further tumour regression with virtually no vis-
ible tumour.
Five animals from each group were moni-
tored and survival curves were established.
Control HBSS treated animals died between
days 48 and 77 (median survival 63 days) while
rats injected with the FLYA13 TK retrovirus
producing cells and treated with GCV died
between days 54 and 136 (median survival 72
days), thus showing an increased survival time
(fig 2). In this experiment, the survival
diVerence failed to reach significance (log rank
test p=0.1).
However, the combination of cytokine gene
therapy and HSV-TK/GCV gene therapy
resulted in significantly improved survival rates
(log rank test p<0.05) with a large proportion
of animals remaining tumour free. Indeed,
60% of animals treated with FLYA13 TK/
GCV in combination with FLYA13 GM-CSF
and 40% of animals treated with FLYA13
TK/GCV and FLYA13 IL-12 were still alive on
day 480 (fig 2).
HISTOLOGICAL ANALYSIS AND
IMMUNOHISTOCHEMICAL STUDIES
Standard histology of untreated tumours has
been described previously.27 Briefly,
haematoxylin-eosin stained sections of the
tumour tissues, harvested on days 14, 21, and
27, revealed sheets or nodules of poorly diVer-
entiated epithelial cells surrounded by a fibrous
stroma with a focally extensive desmoplastic
reaction. Mononuclear cells with scattered
eosinophilic granulocytes were also found
interspersed between the tumour nodules (fig
3A). In treated rats, the main diVerence was
replacement of some or, in some cases, all can-
cer nodules by an extensive mononuclear cell
infiltrate. These inflammatory cells were ob-
served around necrotic or tumour areas but
were also found to infiltrate these areas (fig
3B). No major changes in these histological
features were observed between the diVerent
treatments.
Immunohistological analysis of untreated
tumours showed that lymphoid CD4+ and
CD8+ T cells as well as macrophages accumu-
lated outside the tumour nodes (fig 4, table 1).
After TK/GCV gene therapy, the tumours were
heavily infiltrated by CD8+ cytotoxic T cells
and macrophages (fig 4, table 1). We did not
observe any significant diVerence after treat-
ment with TK/GCV in combination with
IL-12 or GM-CSF compared with TK/GCV
alone regarding CD8+ T cell or macrophage
infiltration. However, the number of CD25+
activated T cells infiltrating the tumour was
higher after combined therapies (table 1).
Discussion
Peritoneal carcinomatosis remains a major
clinical problem as neither surgery nor chemo-
therapy can eradicate these tumours. Thus
Figure 4 Immunohistochemical staining using anti-CD8+ (1), antimacrophage (2),
anti-CD25+ (3), or anti-NK cell (4) antibodies on frozen sections of tumours from control
(left) or treated (right) animals (250× magnification).
Table 1 Immunostaining of lymphoid and macrophagic cells infiltrating the tumours after
thymidine kinase/ganciclovir (TK/GCV) or combined TK/GCV/interleukin 12 (IL-12) or
TK/GCV/granulocyte macrophage-colony stimulating factor (GM-CSF) treatments. Shown
are the average scores after immunostaining with the diVerent antibodies (arbitrary scale
graded from − to +++). In each case, control untreated animals were compared with animals
that had received one (day 14), two (day 21), or three (day 27) courses of retrovirus
producing cells plus GCV. In treated animals, few biopsies showed any residual tumours and
the proportion of tumour free biopsies for each condition is indicated in the first column.Results
are given separately for the tumour (T) itself and the stroma (S) corresponding to the corona
of inflammatory cells surrounding the tumour
Tumour free
CD8 CD25 ED1
samples T S T S T S
Controls 0% − + − − + +
HSV-TK/GCV 55% ++ +++ − + + +++
HSV-TK/GCV+IL-12 83% ++ +++ + + +++ +++
HSV-TK/GCV+GM-CSF 20% ++ +++ + + + ++
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novel therapeutic approaches are required to
treat these cancers which may constitute a
suitable model for gene therapy.
We previously demonstrated that three
injections of retrovirus producing FLYA13 TK
cells followed by GCV treatment significantly
increased the survival rate of rats bearing
extensive DHD/K12 derived peritoneal
carcinomatosis.4 Nevertheless, very few treated
animals remained tumour free (10%), confirm-
ing that the TK gene alone rarely eradicates
established solid tumours.4 6
One way of improving HSV-TK gene
therapy is to boost the bystander eVect. Several
studies have reported that the immune system
participates in the bystander eVect following
TK/GCV gene therapy.28–33 For example, sev-
eral groups highlighted the failure of immuno-
deficient or sublethally irradiated mice to reject
HSV-TK transfected tumours after GCV
treatment, indicating that the bystander eVect
relies in part on an intact immune system.32 33
Therefore, if HSV-TK/GCV treatment de-
pends on the development of an antitumour
immune response to achieve long term remis-
sion, its success should be improved by
concomitant stimulation of the immune sys-
tem. As antigens are released after HSV-TK/
GCV gene therapy, simultaneous local expres-
sion of appropriate cytokines could initiate
such an eVect.34 35 Indeed, a few studies have
demonstrated that the eYcacy of TK/GCV
gene therapy is improved by simultaneous
administration of the IL-2 gene or by a combi-
nation of the IL-2 and GM-CSF genes.36–38
In the present study, when FLYA13 IL-12 or
FLYA13 GM-CSF cells were combined with
FLYA13 TK cells, a highly significant increase
in survival was observed. Moreover, 60% and
40% of TK/GM-CSF and TK/IL-12 treated
rats, respectively, were apparently free of
tumour on day 480 and could be considered as
cured.
HSV-TK/GCV gene therapy leads to necro-
sis in several tumour models.30 33 Tumour anti-
gens are thus available to the immune system
and may activate an antitumour immune
response through uptake and presentation by
antigen presenting cells (APC). GM-CSF is
known to induce APC diVerentiation and may
promote maturation of APC previously at-
tracted to the tumour site by TK/GCV
treatment, rendering them more eVective.
In contrast, several groups have previously
described a Th1 immune response after HSV-
TK/GCV therapies in diVerent models.29 IL-12
is a proinflammatory cytokine which enhances
CD8+ T cell cytolytic activity and supports the
diVerentiation of Th1 helper CD4+ T cells. In
situ production of IL-12 may enhance this Th1
immune response pathway, generating cyto-
toxic CD8+ T cells.
Indeed, co-expression of GM-CSF or IL-12
with the TK gene led to improved survival in
our model, suggesting that a better antigen
presentation or a more eYcient Th 1 response
could improve TK therapeutic activity.
Tumour infiltration by CD8+ T cells and mac-
rophages after TK/GCV gene therapy confirms
that such a treatment induces an immune
response, as previously suggested by several
studies; however, we did not observe significant
diVerences in the immune infiltrates generated
by the three therapeutic strategies. But al-
though the number of infiltrating lymphoid or
macrophagic cells remained approximately
equivalent, animals treated with cytokine genes
in addition to TK/GCV probably developed a
more eVective antitumour immune response.
Our data confirm that an immune reaction is
associated with TK/GCV gene therapy and
indicate that a strategy combining a suicide gene
and cytokine genes may be a way of improving
the results of gene therapy. Interestingly, boost-
ing the immune response may also have an
eVect on lesions away from the injected tumour,
such as micrometastases. Indeed, several obser-
vations indicate that, under certain experimen-
tal conditions, suicide gene therapy can induce
a systemic immune response, capable of medi-
ating regression of distant metastases after
eradication of a localised cytosine deaminase or
thymidine kinase expressing tumour.39 40
In conclusion, our data confirm that suicide
genes have only a limited eYcacy and that their
antitumour activity may be increased by simul-
taneous expression of cytokine genes. Clinical
trials should be considered with combined
therapies.
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